The NCRI Lymphoma Group brings together clinicians, scientists and patients, carers and others affected by cancer (also known as ‘consumers’), amongst many others, to coordinate the development of a strategic portfolio of research within the field of lymphoma. The group works closely with clinical research networks, funders and researchers to develop research to improve outcomes for lymphoma patients.  

The NCRI Lymphoma Group consists of an executive group, chaired by Professor Andrew Pettittwhich provides oversight of the research landscape and proactively identifies opportunities for the group. The NCRI Lymphoma Group also has several subgroups that develop research in areas of strategic need. 

How can I get involved?

Join the NCRI Lymphoma Network

Group members

Professor Andrew Pettitt

Professor Andrew Pettitt

Chair

I studied Medicine at Cambridge (1983-1989) before taking up clinical training posts in Internal ...

Professor Andrew Pettitt

Chair

I studied Medicine at Cambridge (1983-1989) before taking up clinical training posts in Internal Medicine (Nottingham, 1990-1992) and Haematology (Liverpool, 1992-2000), during which time I completed a PhD on drug resistance in chronic lymphocytic leukaemia (CLL). In 2000, I was appointed as Clinical Senior Lecturer in Haematology at the University of Liverpool, with subsequent promotion to Reader (2004), Personal Chair (2006) and Ronald Finn Professor of Experimental Medicine (2013). University leadership roles include Head of Department of Molecular and Clinical Cancer Medicine (2011-2020) and Chair of the Clinical Trials Oversight Committee (from 2018). In addition, I am an Honorary Consultant Haemato-oncologist at the Clatterbridge Cancer Centre NHS Foundation Trust, as well as Director of the Liverpool Health Partners Cancer Programme (from 2019) and inaugural Director of the Liverpool Cancer Research Institute (from 2020). At national level, I am Chair of the National Cancer Research Institute (NCRI) Lymphoma Research Group (from 2017), having previously chaired the NCRI Haematological Oncology Clinical Studies Group (2012-2017) and UK CLL Forum (2006-2012). I represent the UK in the European Lymphoma Institute (from 2019).

Professor Andrew Davies

Incoming Chair

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty ...

Professor Andrew Davies

Incoming Chair

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Prof. Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena.  He has extensive experience in early phase trials, including leading several first in man lymphoma studies.

He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

Dr Graham Collins

Incoming Deputy Chair

Dr Collins trained in medicine at Cambridge and London before undergoing haematology training at ...

Dr Graham Collins

Incoming Deputy Chair

Dr Collins trained in medicine at Cambridge and London before undergoing haematology training at Oxford, completing a DPhil in the molecular biology of the Reed-Sternberg cell. He is now lymphoma lead clinician for the Thames Valley cancer network and consultant at the Churchill hospital in Oxford. His research interests are in Hodgkin and aggressive non-Hodgkin lymphoma and has lead both the Hodgkin and T-cell lymphoma national study groups. He leads a number of investigator-initiated trials, has contributed to several national clinical guidelines and works on a number of projects with the National Institute of Health and Care Excellence (NICE). He is clinical expert on the national CAR-T panel for lymphoma and co-course director for the national Lymphoma management course.